Brain‐Targeted Black Phosphorus‐Based Nanotherapeutic Platform for Enhanced Hypericin Delivery in Depression

Depression is a significant global health concern that remains inadequately treated due to the limited effectiveness of conventional drug therapies. One potential therapeutic agent, hypericin (HYP), is identified as an effective natural antidepressant. However, its poor water solubility, low bioavailability, and limited ability to penetrate the brain parenchyma have hindered its clinical application. To address these shortcomings and enhance the therapeutic efficacy of HYP, it is loaded onto black phosphorus nanosheets (BP) modified with the neural cell‐targeting peptide RVG29 to synthesize a nanoplatform named BP‐RVG29@HYP (BRH). This platform served as a nanocarrier for HYP and integrated the advantages of BP with advanced delivery methods and precise targeting strategies. Under the influence of 808 nm near‐infrared irradiation (NIR), BRH effectively traversed an in vitro BBB model. In vivo experiments validated these findings, demonstrating that treatment with BRH significantly alleviated depressive‐like behaviors and oxidative stress in mice. Importantly, BRH exhibited an excellent safety profile, causing minimal adverse effects, which highlighted its potential as a promising therapeutic agent. In brief, this novel nanocarrier holds great promise in the development of antidepressant drugs and can create new avenues for the treatment of depression. This article explores the breakthrough in depression treatment through the novel nanoplatform BP‐RVG29@HYP (BRH), which effectively overcomes the blood‐brain barrier challenges. Leveraging black phosphorus nanosheets and advanced delivery methods, BRH significantly alleviates depressive symptoms and oxidative stress in mice, with minimal side effects. This pioneering approach marks a significant stride in antidepressant drug development.